OACP4 C

Description

• Cell Line Description: OACP4 C was established from a primary tumour located in gastric cardia of a 55 year-old Caucasian male. The patient showed lymph node involvement with pleural metastases. OACP4 C was found to be tumourigenic in NMRI (female nude mice or NOD-SCID mice. The Y chromosome could not be detected in this cell line by short tandem repeat (STR)-PCR analysis when tested at ECACC. It is a known phenomenon that due to the increased genetic instability of cancer cell lines the Y chromosome can be rearranged or lost resulting in lack of detection. The cell line is identical to the source provided by the depositor based on the STR-PCR analysis.Cultures derived from ECACC stocks of this cell line have been whole genome sequenced (Contino, et al 2016) confirming the presence of many of the known mutations that drive oesophageal cancer.
• DNA Profile: STR-PCR Data:Amelogenin: XCSF1PO: 11D13S317: 12D16S539: 12D5S818: 9D7S820: 9,11THO1: 9TPOX: 11vWA: 16
• Culture Medium: RPMI 1640 (R0883) + 2 mM L-Glutamine (G7513) + 10% FBS (F2442)
• Subculture Routine: Split sub-confluent cultures (70-80%) up to 1:5 i.e. seeding at 1-3 x 10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C.
• Other Notes: Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
• Citation: If use of this culture results in a scientific publication, it should be cited in the publication as: OACP4 C (ECACC 11012005)
• Disclaimer: RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.